explore -WSS

explore

author：hotspot 2025-10-01 23:39:25 - browse：4653

Dr. Peter Bach — Peter Bach, shown at the 2019 STAT summit, is now chief medical officer of Delfi. Emilie Pickering for STAT

Delfi Diagnostics, a well-funded startup in the burgeoning field of creating blood tests to detect cancer, said on Monday that it is launching a new test, FirstLook Lung, to try to identify people who could most benefit from lung cancer screening.

The approach represents a new one in the field of liquid biopsy, in which DNA fragments in blood are used to detect or learn about tumors. Grail, another company developing a blood test for cancer screening, has insisted that its product would be best used to detect multiple cancers at once. Other companies, including Exact Sciences and Freenome, are developing tests that would focus on detecting colorectal cancer. But Delfi appears to be the first to focus first on lung cancer, the leading cause of cancer death.

Delfi’s executives, in an interview with STAT, were clear that they view the initial launch as an opportunity to gather information, and not a real commercial coming out. The test will likely become available in limited ways with specific partners and will not initially be covered by insurance. Delfi declined to reveal a specific price, but said that its early access customers, which it is not yet disclosing, will be able to use FirstLook Lung for several hundred dollars. Such a rollout does not require approval from the Food and Drug Administration, which Delfi does not have.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： ALS advocates say criticism of new drugs misses bigger picture

WSS

Four alarming medical procedures we’re glad history forgot

NIH nominee Bertagnolli will get October confirmation hearing

Stem cell treatment guidelines are released by FDA

Weighted lottery helped low

A new House health package & hospitals’ new site

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

knowledge

explore

hotspot

Affirmative action in medical school literally saved lives

Insurer loopholes limit power of law against surprise medical bills

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Medicare Advantage 2025 payments will dip, Biden administration says

Tori Bowie and the unacceptable rates of Black maternal death

Pancreatic cancer is often deadly, but new discoveries are raising hope

Alkermes shareholders re

Trial using CRISPR to edit HIV out of cells disappoints

How to save PrEP access — and even expand it

Stem cell treatment guidelines are released by FDA

Wikipedia

Snackable artificial intelligence, expert AI, and the pharma industry

A rare thyroid diagnosis led to unexpected, all

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

AstraZeneca chief proposes a novel edit to the drug pricing bill

Multiple sclerosis has subtypes with different best treatments: study

Multiple sclerosis has subtypes with different best treatments: study

hotspot

hotspot

entertainment

knowledge